Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 13,586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

NCT07775313
View directory record Official record
Conditions
WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
Interventions
Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

NCT03347123
View directory record Official record
Conditions
Solid Tumors
Interventions
Epacadostat, Nivolumab, Ipilimumab, Lirilumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Early Phase 1 Interventional Results available

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

NCT01398280
View directory record Official record
Conditions
Rosacea
Interventions
Topical aminocaproic acid (ACA) mixed with Vanicream, Vehicle cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting Phase 1 Interventional

Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1

NCT07216183
View directory record Official record
Conditions
Transtibial Amputation
Interventions
Walk, Yuga post, E-SWEAT Sensor
Procedure · Device
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

NCT04019041
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
Interventions
bermekimab, placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Gilbert, Arizona • Huntington Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 24, 2026, 9:16 AM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

NCT02102490
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

NCT01885910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 100mg, Aczone 5% gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs

NCT04170920
View directory record Official record
Conditions
Breast Cancer, DCIS
Interventions
LifeExtend-AI
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396
View directory record Official record
Conditions
Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
Interventions
flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

NCT00001764
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

NCT02815332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
9 Years to 40 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

NCT04163263
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
BOS-356, Vehicle
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Fremont, California • Sanford, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

NCT03338816
View directory record Official record
Conditions
Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions
Givosiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 24, 2026, 9:16 AM EDT
Active, not recruiting Phase 2 Interventional

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions
PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Withdrawn Phase 3 Interventional

MC RCT - BPO vs Adapalene

NCT05536882
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Benzoyl peroxide, Adapalene Gel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 14 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting No phase listed Observational

International Rare Histiocytic Disorders Registry (IRHDR)

NCT02285582
View directory record Official record
Conditions
Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Xanthogranuloma Family (XG), Indeterminate Dendritic Cell Histiocytosis, Malignant Histiocytic Neoplasm (MHN), ALK-positive Histiocytosis, Mixed Histiocytosis (MXH), Multicentric Reticulohistiocytoma (MRH), Necrobiotic Xanthogranuloma (NX)
Interventions
Registry study
Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 24, 2026, 9:16 AM EDT
Withdrawn Phase 2 Interventional

Erlotinib for Treatment of Psoriasis

NCT01006096
View directory record Official record
Conditions
Psoriasis
Interventions
erlotinib, placebo tablet
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 24, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury

NCT03317288
View directory record Official record
Conditions
Spinal Cord Injuries, Pressure Ulcer
Interventions
Dabir Air overlay
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 24, 2026, 9:16 AM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 24, 2026, 9:16 AM EDT